Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

AbCellera Biologics (8QQ) Stock Price & Analysis

8QQ Stock Chart & Stats

€11.30-€0.46(-3.91%)
At close: 5:30 PM GMT+1
EUR 5EUR 7.5EUR 10EUR 12.53 Aug17 Aug1 Sep14 Sep28 Sep12 Oct26 Oct
Day’s Range
EUR 11.30 - EUR 11.30
52-Week Range
EUR 2.49 - EUR 12.96
Previous Close
EUR 11.76
Volume
130
Average Volume (3M)
143
Market Cap
EUR 3.55B
Enterprise Value
EUR 1.97B
Total Cash (Recent Filing)
EUR 540.10M
Total Debt (Recent Filing)
EUR 135.62M
Price to Earnings (P/E)
―
Beta
1.37
Next Earnings
Nov 09, 2026 (Est.)
EPS Estimate
-0.15
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Liquidity And Funding Runway

Substantial liquidity gives AbCellera financial capacity to fund clinical development and platform investment without relying solely on near-term operating revenue. Management says available resources support at least three years of pipeline investment, improving strategic flexibility through upcoming development milestones.

Strategic Partnership Economics

Large partnership proceeds validate the commercial relevance of AbCellera’s technology while providing non-dilutive funding for internal programs. Potential milestones and tiered royalties could create durable future value if partnered assets advance, diversifying returns beyond research fees.

Technology Platform And Partner Traction

A developed T-cell engager toolkit and repeated interest from major biopharma partners suggest a reusable discovery capability rather than dependence on one asset. This platform can support additional collaborations and broaden the pipeline over multiple development cycles.

Bears Say

Persistent Operating Losses

Large sustained operating losses show that the current revenue base does not yet support AbCellera’s cost structure, despite a relatively healthy gross margin. Continued losses can consume equity and increase dependence on partnerships, financing, or successful clinical outcomes to fund growth.

Negative Cash Generation And Revenue Dependence

Negative operating and free cash flow indicate that AbCellera is not currently self-funding its operations. The limited recurring revenue base and reliance on research fees or partner payments make cash generation sensitive to collaboration timing, while ongoing investment keeps funding needs elevated.

Clinical And Development Execution Risk

The internal pipeline remains exposed to both scientific uncertainty and execution delays. ABCL635’s efficacy interpretation may be affected by pronounced placebo response, while missed development milestones could postpone future clinical catalysts and extend the period before programs generate meaningful value.

AbCellera Biologics News

8QQ FAQ

What was AbCellera Biologics’s price range in the past 12 months?
AbCellera Biologics lowest stock price was €2.49 and its highest was €12.96 in the past 12 months.
What is AbCellera Biologics’s market cap?
AbCellera Biologics’s market cap is €3.55B.
When is AbCellera Biologics’s upcoming earnings report date?
AbCellera Biologics’s next earnings report is estimated for Nov 09, 2026 (not yet confirmed), which is in 8 days.
How were AbCellera Biologics’s earnings last quarter?
AbCellera Biologics released its earnings results on Aug 05, 2026. The company reported -€0.161 earnings per share for the quarter, missing the consensus estimate of -€0.146 by -€0.014.
Is AbCellera Biologics overvalued?
According to Wall Street analysts AbCellera Biologics’s price is currently Undervalued.
Does AbCellera Biologics pay dividends?
AbCellera Biologics does not currently pay dividends.
What is AbCellera Biologics’s EPS estimate?
AbCellera Biologics’s EPS estimate is -0.15.
How many shares outstanding does AbCellera Biologics have?
AbCellera Biologics has 324,047,360 shares outstanding.
What happened to AbCellera Biologics’s price movement after its last earnings report?
AbCellera Biologics reported an EPS of -€0.161 in its last earnings report, missing expectations of -€0.146. Following the earnings report the stock price went up 4.523%.
Which hedge fund is a major shareholder of AbCellera Biologics?
Hedge funds hold AbCellera Biologics shares: the largest hedge-fund position in AbCellera Biologics is 904,260,129 shares, and hedge funds increased their holdings by 1.5M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology